PDGFR blockade either by imatinib or nilotinib has been shown to have an inhibitory effect on T cells proliferation and survival [63, 64]; however we failed to see such reduction in percentage of CD8+ T cells in spleen of 4 T1.2 nilotinib treated tumours. This evidence concerns the gene PDGFRB and neoplasm.